Skip to main content
SpringerLink
Log in

Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive–compulsive symptoms

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Clinical observations indicate that atypical antipsychotics, especially clozapine, induce obsessive–compulsive (OC) symptoms in schizophrenia patients. Recent data from neuroimaging and clinical trials suggest a role for altered glutamate neurotransmission in the etiology of OC disorder (OCD), and SLC1A1, GRIN2B, and GRIK2 have all been reported to regulate glutamate transmission and affect OCD pathophysiology.

Objectives

This study aimed to determine whether SLC1A1, GRIN2B, and GRIK2 are associated with clozapine-induced OC symptoms.

Methods

A total of 250 clinically stable schizophrenia patients receiving clozapine treatment were recruited. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) was used to evaluate the severity of OC symptoms. Based on their Y-BOCS scores, 250 patients were divided into the OC and non-OC groups (patients with or without OC symptoms, respectively). Additionally, three reported OCD susceptibility polymorphisms, SLC1A1 (rs2228622), GRIN2B (rs890), and GRIK2 (rs1556995), were genotyped.

Results

Trends of association with OC symptoms were observed in rs2228622A and rs890T alleles. SLC1A1 and GRIN2B interaction was found in the significant two-locus gene–gene interaction model (p = 0.0021), using the multifactor dimensionality reduction method. Further analysis showed a significant interaction between SLC1A1 and GRIN2B on the Y-BOCS score (F 6, 137 = 7.650, p < 0.001), and individuals with AA/TT genotypes had a significantly higher mean Y-BOCS score than those with other genotypes, except AG/TT.

Conclusions

These results suggest that SLC1A1, GRIN2B, and interactions between the two may potentially confer a susceptibility to OC symptoms in schizophrenia patients receiving clozapine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Arnold PD, Rosenberg DR, Mundo E, Tharmalingam S, Kennedy JL, Richter MA (2004) Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) 174:530–538

    Article  CAS  Google Scholar 

  • Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL (2006) Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry 63:769–776

    Article  PubMed  CAS  Google Scholar 

  • Arnold PD, Macmaster FP, Hanna GL, Richter MA, Sicard T, Burroughs E, Mirza Y, Easter PC, Rose M, Kennedy JL, Rosenberg DR (2009) Glutamate system genes associated with ventral prefrontal and thalamic volume in pediatric obsessive-compulsive disorder. Brain Imaging Behav 3:64–76

    Article  PubMed  Google Scholar 

  • Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Leucht S (2010) Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev CD006633

  • Atmaca M, Yildirim H, Ozdemir H, Aydin A, Tezcan E, Ozler S (2006) Volumetric MRI assessment of brain regions in patients with refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 30:1051–1057

    Article  PubMed  Google Scholar 

  • Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S (2005) Glutamatergic dysfunction in OCD. Neuropsychopharmacology 30:1735–1740

    Article  PubMed  CAS  Google Scholar 

  • Conne B, Stutz A, Vassalli JD (2000) The 3′ untranslated region of messenger RNA: a molecular ‘hotspot’ for pathology? Nat Med 6:637–641

    Article  PubMed  CAS  Google Scholar 

  • de Haan L, Linszen DH, Gorsira R (1999) Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. J Clin Psychiatry 60:364–365

    Google Scholar 

  • Delorme R, Krebs MO, Chabane N, Roy I, Millet B, Mouren-Simeoni MC, Maier W, Bourgeron T, Leboyer M (2004) Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder. Neuroreport 15:699–702

    Article  PubMed  CAS  Google Scholar 

  • Dickel DE, Veenstra-VanderWeele J, Cox NJ, Wu X, Fischer DJ, Van Etten-Lee M, Himle JA, Leventhal BL, Cook EH Jr, Hanna GL (2006) Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry 63:778–785

    Article  PubMed  CAS  Google Scholar 

  • Ertugrul A, Anil Yagcioglu AE, Eni N, Yazici KM (2005) Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients. Psychiatry Clin Neurosci 59:219–222

    Article  PubMed  Google Scholar 

  • Evins AE, Amico ET, Shih V, Goff DC (1997) Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J Neural Transm 104:761–766

    Article  PubMed  CAS  Google Scholar 

  • Fenton WS, McGlashan TH (1986) The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry 143:437–441

    PubMed  CAS  Google Scholar 

  • Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS (1989) The Yale-Brown obsessive compulsive scale. I. Development, use, and reliability. Arch Gen Psychiatry 46:1006–1011

    Article  PubMed  CAS  Google Scholar 

  • Hahn LW, Ritchie MD, Moore JH (2003) Multifactor dimensionality reduction software for detecting gene–gene and gene–environment interactions. Bioinformatics 19:376–382

    Article  PubMed  CAS  Google Scholar 

  • Hollmann M, Heinemann S (1994) Cloned glutamate receptors. Annu Rev Neurosci 17:31–108

    Article  PubMed  CAS  Google Scholar 

  • Jamain S, Betancur C, Quach H, Philippe A, Fellous M, Giros B, Gillberg C, Leboyer M, Bourgeron T (2002) Linkage and association of the glutamate receptor 6 gene with autism. Mol Psychiatry 7:302–310

    Article  PubMed  CAS  Google Scholar 

  • Kayahan B, Ozturk O, Veznedaroglu B, Eraslan D (2005) Obsessive-compulsive symptoms in schizophrenia: prevalence and clinical correlates. Psychiatry Clin Neurosci 59:291–295

    Article  PubMed  Google Scholar 

  • Khullar A, Chue P, Tibbo P (2001) Quetiapine and obsessive–compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J Psychiatry Neurosci 26:55–59

    PubMed  CAS  Google Scholar 

  • Kwon JS, Joo YH, Nam HJ, Lim M, Cho EY, Jung MH, Choi JS, Kim B, Kang DH, Oh S, Park T, Hong KS (2009) Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Arch Gen Psychiatry 66:1233–1241

    Article  PubMed  CAS  Google Scholar 

  • Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223

    Article  PubMed  CAS  Google Scholar 

  • Liu BC, Zhang J, Wang L, Li XW, Wang Y, Ji J, Yang FP, Wan CL, Gao LH, Xu YF, Feng GY, He L, Zhao XZ, He G (2010) No association between EGR gene family polymorphisms and schizophrenia in the Chinese population. Prog Neuropsychopharmacol Biol Psychiatry 34:506–509

    Article  PubMed  CAS  Google Scholar 

  • Marazziti D, Carlini M, Dell'Osso L (2012) Treatment strategies of obsessive-compulsive disorder and panic disorder/agoraphobia. Curr Top Med Chem 12:238–253

    Article  PubMed  CAS  Google Scholar 

  • McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600–610

    Article  PubMed  Google Scholar 

  • Ongur D, Goff DC (2005) Obsessive–compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status. Schizophr Res 75:349–362

    Article  PubMed  Google Scholar 

  • Pauls DL (2008) The genetics of obsessive compulsive disorder: a review of the evidence. Am J Med Genet C Semin Med Genet 148C:133–139

    Article  PubMed  Google Scholar 

  • Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ (2000) Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 39:1096–1103

    Article  PubMed  CAS  Google Scholar 

  • Ryu S, Oh S, Cho EY, Nam HJ, Yoo JH, Park T, Joo YH, Kwon JS, Hong KS (2011) Interaction between genetic variants of DLGAP3 and SLC1A1 affecting the risk of atypical antipsychotics-induced obsessive–compulsive symptoms. Am J Med Genet B Neuropsychiatr Genet 156B:949–959

    PubMed  Google Scholar 

  • Sa AR, Hounie AG, Sampaio AS, Arrais J, Miguel EC, Elkis H (2009) Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. Compr Psychiatry 50:437–442

    Article  PubMed  Google Scholar 

  • Sampaio AS, Fagerness J, Crane J, Leboyer M, Delorme R, Pauls DL, Stewart SE (2011) Association between polymorphisms in GRIK2 gene and obsessive-compulsive disorder: a family-based study. CNS Neurosci Ther 17:141–147

    Article  PubMed  CAS  Google Scholar 

  • Samuels J, Wang Y, Riddle MA, Greenberg BD, Fyer AJ, McCracken JT, Rauch SL, Murphy DL, Grados MA, Knowles JA, Piacentini J, Cullen B, Bienvenu OJ 3rd, Rasmussen SA, Geller D, Pauls DL, Liang KY, Shugart YY, Nestadt G (2011) Comprehensive family-based association study of the glutamate transporter gene SLC1A1 in obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 156B:472–477

    PubMed  Google Scholar 

  • Schirmbeck F, Zink M (2012) Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol 10:88–95

    Article  PubMed  CAS  Google Scholar 

  • Schirmbeck F, Esslinger C, Rausch F, Englisch S, Meyer-Lindenberg A, Zink M (2011) Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol Med 41:2361–2373

    Article  PubMed  CAS  Google Scholar 

  • Shi YY, He L (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15:97–98

    Article  PubMed  CAS  Google Scholar 

  • Stewart SE, Fagerness JA, Platko J, Smoller JW, Scharf JM, Illmann C, Jenike E, Chabane N, Leboyer M, Delorme R, Jenike MA, Pauls DL (2007) Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet 144B:1027–1033

    Article  PubMed  CAS  Google Scholar 

  • van Grootheest DS, Cath DC, Beekman AT, Boomsma DI (2005) Twin studies on obsessive–compulsive disorder: a review. Twin Res Hum Genet 8:450–458

    PubMed  Google Scholar 

  • Wu K, Hanna GL, Rosenberg DR, Arnold PD (2012) The role of glutamate signaling in the pathogenesis and treatment of obsessive–compulsive disorder. Pharmacol Biochem Behav 100:726–735

    Article  PubMed  CAS  Google Scholar 

  • Zhang C, Li Z, Shao Y, Xie B, Du Y, Fang Y, Yu S (2011) Association study of tryptophan hydroxylase-2 gene in schizophrenia and its clinical features in Chinese Han population. J Mol Neurosci 43:406–411

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We are deeply grateful to all participants. This work was supported by the National Natural Science Foundation of China (81000581), Shanghai Science & Technology Development Foundation (12140904200), and the National Key Clinical Disciplines at Shanghai Mental Health Center (OMA-MH2011-873).

Author information

Authors and Affiliations

  1. Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People’s Republic of China

    Jun Cai, Zhenghui Yi, Weihong Lu & Chen Zhang

  2. Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Kunming, 650223, Yunnan, People’s Republic of China

    Wen Zhang & Chen Zhang

  3. Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People’s Republic of China

    Zhiguo Wu, Jun Chen & Yiru Fang

  4. Department of Genetics, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People’s Republic of China

    Shunying Yu

Authors
  1. Jun Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhenghui Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Weihong Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhiguo Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shunying Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yiru Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yiru Fang or Chen Zhang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cai, J., Zhang, W., Yi, Z. et al. Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive–compulsive symptoms. Psychopharmacology 230, 49–55 (2013). https://doi.org/10.1007/s00213-013-3137-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-013-3137-2

Keywords

Search

Navigation